Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 7Phase 3 3Phase 1/2 2Phase NA 1Phase 4 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Recurrence 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × talquetamab × Clear all
NCT05552222 2026-05-08

MajesTEC-7

Janssen Research & Development, LLC

Phase 3 Recruiting
1,590 enrolled
Plasma cell

Multiple Myeloma

NCT05455320 2026-04-13

MonumenTAL-3

Janssen Research & Development, LLC

Phase 3 Active not recruiting
864 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT06208150 2026-03-13

MonumenTAL-6

Janssen Research & Development, LLC

Phase 3 Recruiting
795 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡